Is 'Bodega Reta' Safe? What Lab Tests of Gray-Market Retatrutide Found

No, there is no way to call "bodega Reta" safe. When CBS News had a vial labeled retatrutide from a Brooklyn corner store tested in October 2026, the lab found no peptide at all: a filler called phenylacetic acid plus 13 colonies of bacteria. Retatrutide is still an investigational Eli Lilly drug. It is not FDA-approved, and neither is anything sold under its name.

A plain note first: this is news and research, not medical advice. It contains no dosing, sourcing, or how-to information, on purpose. If you are using or thinking about any weight-loss drug, talk to a doctor or pharmacist. If you have symptoms like chest pain, trouble breathing, severe vomiting, fainting, or a fast heartbeat after injecting anything, seek emergency care now: call 911 in the US or Canada, or 000 in Australia.

What is "bodega Reta"?

"Reta" is internet shorthand for retatrutide, Lilly's experimental triple agonist (it acts on GIP, GLP-1, and glucagon receptors). "Bodega Reta" is what people call vials sold as retatrutide over the counter in convenience stores, usually labeled "research use only."

CBS News first reported on it on July 2, 2026, describing a Brooklyn bodega with a "PEPTIDES SOLD HERE" sign and a cashier who rang up a vial with "no age verification, no medical questionnaire, no prescription needed." The poster in the window promoted it for "weight management," while the small print said "not for human consumption."

That contradiction is the whole story in one sentence. A label that says "not for humans" next to a poster selling a human benefit is not a loophole. The FDA says it has warned companies selling retatrutide and other GLP-1 type drugs "falsely labeled 'for research purposes' or 'not for human consumption'" that were sold to consumers for human use.

For the full trial picture, see our explainer on retatrutide and research peptides. This post is about what is actually inside the gray-market vials.

What did the lab tests find?

CBS News published its lab results on October 21, 2026. A CBS correspondent bought three products sold as retatrutide: two from websites and one from a Brooklyn bodega. University of Iowa research scientist Jason Galpin analyzed them.

Sample	What CBS reported	What it does not tell you
Two online purchases	"Consistent with a basic standard" Galpin created for retatrutide, which CBS notes "isn't the same as the drug being studied" in Lilly's trials	Nothing about sterility, exact dose, stability, or the next vial
Bodega vial	"It does not look anything like a peptide," Galpin said. Main compound: phenylacetic acid, which he called a filler	That any retatrutide was present at all
Bodega vial, microbiology	Carl Ross of the University of Iowa's Center for Biocatalysis and Bioprocessing found 13 colonies of bacteria	Which bacteria, or how many more vials look like this

Ross explained the risk plainly: "As kids, we're all taught to wash out cuts if we get cut, but in this case … we're injecting bacteria under the skin where it could multiply. It's pretty terrifying."

Yale physician Dr. Reshma Ramachandran told CBS that people buying these products are essentially acting as guinea pigs, because the drug "has not been certified as safe and effective."

Futurism picked up the results on October 24, 2026, noting that phenylacetic acid is used in perfume. WIRED ran a similar bodega test in September, which Futurism summarized as vials that "weren't peptides at all."

"But my vial passed a test"

Two of the three CBS samples did look like retatrutide on a basic check. That is not the same as safe. Lilly's statement to CBS made the point bluntly: "A single test is a snapshot, not a guarantee that the dose will be sterile or stable in two weeks, let alone that the next vial will be safe."

And the paperwork can be fake too. In its July report, CBS found that a seller's posted certificate of analysis for retatrutide showed a graph that appeared to identify a different drug, tirzepatide. The lab named on the certificate told CBS: "We did not issue these."

Have people died from gray-market retatrutide?

Two deaths have been reported to the FDA, but it is not proven that the products caused them. On October 13, 2026, CBS News reported FDA adverse event documents it obtained through a public records request:

• July 2026: a 41-year-old woman went into cardiac arrest. The report listed retatrutide as a "suspect product" obtained "from an unreliable source."
• September 2026: a 49-year-old patient died after experiencing "severe dehydration, malnutrition and cardiac arrest." The report says a licensed nurse "convinced" her to buy retatrutide from an online vendor.

CBS stressed that it could not verify the reports and that "it is unclear whether the drug was to blame." The FDA declined to say whether it had verified them. Lilly said the reports "make clear the two individuals were taking black-market retatrutide."

The same CBS report cited America's Poison Centers, which logged 862 retatrutide exposures in the three months ending September 2026, up from 460 the quarter before and 249 in the first three months of 2026. That is about 3.5 times the early-2026 count in two quarters.

Quarter (2026)	Retatrutide exposures logged by America's Poison Centers
January to March	249
April to June	460
July to September	862

What is happening in Australia?

Australia has some of the clearest data so far. On October 20, 2026, the RACGP's newsGP reported a NSW Health analysis of emergency department visits linked to unapproved peptides from July 1, 2025 to the end of September 2026:

• Presentations rose from 5 a month to 217 a month
• 1,180 presentations in total, and 18% were admitted to hospital
• 71% were linked to retatrutide
• Most were gastrointestinal (abdominal pain, nausea, vomiting) or cardiovascular (including chest pain), plus anaphylaxis and allergic reactions
• More than four in five patients were under 45, and the 25 to 34 group was the largest at 32%

Royal Melbourne Hospital emergency director Associate Professor Mark Putland told newsGP that Melbourne EDs are seeing "a big increase," and that these symptoms look a lot like heart attack symptoms, so they need real workups.

Earlier, on September 14, 2026, newsGP reported a TGA warning after a patient was hospitalised with a torn oesophagus following uncontrolled vomiting. The product, sold as retatrutide, contained no retatrutide. It contained undeclared semaglutide at about eight times the level in products on the Australian Register of Therapeutic Goods. The TGA said any retatrutide accessed outside a clinical trial "could be a counterfeit product."

What do Canada and the US say?

Health Canada issued a public advisory on April 9, 2026 titled "Think twice before injecting peptides bought online." Retatrutide is on its list of seized unauthorized injectable peptides. It says these products "have not been assessed for safety, efficacy, and quality," may "contain too much, too little, or none of the active ingredient," and that a "For Research Use Only" label "does not make these products legal." Authorized drugs in Canada carry an 8-digit DIN on the label.

The FDA says, on its unapproved GLP-1 page (current as of October 1, 2026), that "retatrutide and cagrilintide cannot be used in compounding under federal law," are "not components of FDA-approved drugs," and "have not been found safe and effective for any condition." It has warned telehealth companies, ingredient distributors, and outsourcing facilities over retatrutide.

Regulator	Retatrutide status	Key warning
FDA (US)	Not approved; cannot be compounded	"Research" labels on products sold for human use are false
TGA (Australia)	Not approved; in clinical trials	Anything outside a trial could be counterfeit
Health Canada	Unauthorized; seized	"Research use only" does not make it legal

Is real retatrutide effective?

In trials, yes, and that is exactly why the knockoffs exist. TRIUMPH-1, published in the New England Journal of Medicine on September 29, 2026, randomized 2,339 adults with obesity for 80 weeks. Average body weight change in the retatrutide groups ranged from -17.6% to -25.0%, versus -3.9% on placebo. The most common side effects were gastrointestinal. The trial was funded by Lilly.

Those results come from Lilly's drug, made under regulated conditions, given under medical supervision. They say nothing about a vial from a deli. Lilly's August 2026 earnings release said it plans to submit to the FDA in the first quarter of 2027, so approval, if it comes, is still ahead.

What to do instead

If you want help with weight, the safest move is boring and effective: book a doctor. Approved GLP-1 options like Wegovy (semaglutide) and Zepbound (tirzepatide) exist, come with real dosing guidance, and are prescribed with follow-up. Our GLP-1 cost comparison covers what they actually cost.

Questions worth bringing to the appointment:

• Am I a candidate for an approved medication, and which one fits my health history?
• What side effects mean I should call you, and which mean I should go to an ED?
• How much protein and how many calories should I aim for on a smaller appetite?
• If I have already used a gray-market product, what should we check?

Be honest about anything you have used. As Associate Professor Putland told newsGP, doctors would much rather have that conversation than meet you in the ED. And if weight or food has ever felt like a struggle with your body image or a history of disordered eating, please work with a professional who knows that history. Every body deserves care that is actually safe.

Where food tracking fits on an approved plan

Here is the part I can actually help with. On any approved GLP-1, appetite shrinks and meals get tiny, and the FDA approves these drugs alongside a reduced-calorie diet. Food still matters, and protein gets hard to hit when you eat a few bites at a time. Our guide to protein on a GLP-1 goes deep on why.

I built Nouri because my first tracker made a normal dinner take several minutes to enter, and I quit. On a small appetite that friction is even worse: half a yogurt and three bites of chicken do not feel worth a database search. In Nouri, you just type "half a Greek yogurt and a few bites of grilled chicken," say it, snap a photo (Nouri turns it into a sentence first so you can fix it), or say "Hey Siri, track food in Nouri" from the lock screen. Calories and protein come back with per-item reasoning you can check.

Turn on Prioritize Protein and your target moves from 1.0 g to 1.2 g per pound of body weight, with fat at 30% and carbs absorbing the rest. Your prescriber or dietitian should set your personal target; Nouri just keeps it visible. Nouri is a food tracker, not a treatment, and it is not designed for any medication. Unlike a bodega vial, at least it tells you exactly what it thinks is in there.

FAQ

Is bodega retatrutide real?

There is no way to know, and in one test it was not. The bodega vial CBS News tested in October 2026 contained no detectable peptide, just phenylacetic acid and 13 colonies of bacteria.

Is retatrutide FDA approved?

No. It is an investigational Eli Lilly drug still in clinical trials. Lilly has said it plans to submit to the FDA in the first quarter of 2027.

Is "research use only" retatrutide legal?

The FDA calls those labels false when products are sold to consumers for human use, and says retatrutide cannot be compounded. Health Canada says a research-only label does not make a product legal.

What did the CBS News lab test find?

Two online samples matched a basic retatrutide reference, which is not the same as the trial drug and says nothing about sterility. The bodega sample held no peptide, mostly phenylacetic acid, plus 13 bacterial colonies.

Has anyone died from black-market retatrutide?

CBS News reported two deaths in FDA adverse event reports in 2026, in July and September. The reports are unverified and do not prove the products caused the deaths.

What are the side effects of gray-market peptides?

In NSW, most peptide-linked ED visits were gastrointestinal or cardiovascular, plus allergic reactions and anaphylaxis. Contaminated injections can also cause infections, according to Health Canada and the scientists CBS interviewed.

Is retatrutide legal in Australia?

It is not approved in Australia. The TGA says it is in clinical trials and that any retatrutide accessed outside a trial could be counterfeit.

Is retatrutide legal in Canada?

No. Health Canada lists retatrutide among unauthorized injectable peptides it has seized and warns consumers not to buy or use them.

Can a certificate of analysis prove a peptide is safe?

No. CBS found a posted certificate that appeared to show a different drug, and the named lab said it never issued it. Even a genuine test covers one sample, not every vial.

When should I go to the emergency room after injecting a peptide?

Go now for chest pain, trouble breathing, swelling of the face or throat, fainting, a racing heartbeat, or vomiting you cannot stop. Call 911 in the US or Canada, or 000 in Australia.

What should I do instead of buying Reta?

Talk to a doctor about approved options like semaglutide or tirzepatide, which come with real quality control and follow-up. Bring a list of anything you have already used.

What is the easiest way to track food and protein on a GLP-1?

Use a tracker that makes a tiny meal as fast as a big one. In Nouri, "a few bites of salmon and half a cup of rice" is one sentence, typed, spoken, snapped, or said to Siri, and protein shows up against your target right away.

"Bodega Reta" is a mystery vial with a famous name on it, and the tests so far are not reassuring. If you are on an approved plan, keep your meals honest in Nouri, plan your intake with calories on Ozempic, and read our BPC-157 research guide before the next peptide trend hits your feed.

Sources

• CBS News, "We bought and tested what was sold as an experimental weight loss drug. The lab results were 'pretty terrifying,'" October 21, 2026, cbsnews.com (checked Oct 25, 2026)
• CBS News, "Two deaths were reported to the FDA. Is the bootleg weight-loss drug 'Reta' to blame?", October 13, 2026, cbsnews.com (checked Oct 25, 2026)
• CBS News, "What a Brooklyn bodega reveals about the craze for an experimental weight-loss drug," July 2, 2026, cbsnews.com (checked Oct 25, 2026)
• Futurism, "Someone Ran a Chemical Analysis of Bodega Retatrutide and Dear Lord," October 24, 2026, futurism.com (checked Oct 25, 2026)
• RACGP newsGP, "Peptide ED presentations are spiking, what can GPs do?", October 20, 2026, racgp.org.au (checked Oct 25, 2026)
• RACGP newsGP, "Patient suffers torn oesophagus after counterfeit peptide use," September 14, 2026, racgp.org.au (checked Oct 25, 2026)
• Health Canada, "Think twice before injecting peptides bought online: unauthorized products can seriously harm you," RA-81874, April 9, 2026, recalls-rappels.canada.ca (checked Oct 25, 2026)
• FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss," content current as of October 1, 2026, fda.gov (checked Oct 25, 2026)
• Jastreboff AM et al., "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity" (TRIUMPH-1), New England Journal of Medicine, September 29, 2026, pubmed.ncbi.nlm.nih.gov/42814954 (checked Oct 25, 2026)
• Eli Lilly Q2 2026 earnings release (Form 8-K exhibit), August 5, 2026, sec.gov (checked Oct 25, 2026)
• FDA, "FDA Approves New Medication for Chronic Weight Management" (Zepbound), November 8, 2023, fda.gov (checked Oct 25, 2026)